Price$0.42-1.86 (-81.45%)
2026-04-142026-07-17
News · 26 weeks38-56%
2026-01-252026-07-19
Mix1990d
- Insider10(53%)
- SEC Filings3(16%)
- Other3(16%)
- Earnings2(11%)
- Analyst1(5%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by MDxHealth SASCHEDULE 13G/A - MDxHealth SA (0001872529) (Subject)
- SECSEC Form 6-K filed by MDxHealth SA6-K - MDxHealth SA (0001872529) (Filer)
- PRMdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyIRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification. Na
- PRMdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled TrialMdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – June 29, 2026– Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, one of the world’s leading journals in genitourinary oncology. The publication represents the first major peer-reviewed milestone from the Oxford collaboration and serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study.
- INSIDERSEC Form 4 filed by Officer Sollee Joseph4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 4 filed by Director Hardison Don M4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Mcgarrity Michael4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 4 filed by VP, Finance and Accounting Oconnell Brendan4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoffman Koen4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Bellano John4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 4 filed by Director Siegel Sanford Jay4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 4 filed by Director Windels Hilde4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 4 filed by Director Holder Michael4 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Oconnell Brendan3 - MDxHealth SA (0001872529) (Issuer)
- ANALYSTMDxHealth SA downgraded by William BlairWilliam Blair downgraded MDxHealth SA from Outperform to Mkt Perform
- SECSEC Form 6-K filed by MDxHealth SA6-K - MDxHealth SA (0001872529) (Filer)
- PRMdxhealth Reports Q1-2026 ResultsMdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, California – May 13, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2026. Michael K. McGarrity, CEO of mdxhealth, commented: "As we prioritized the integration of our recently acquired ExoDx business and to allow for renewed focus on our core prostate cancer business, we have made the strategic decision to discontinue our Resolve UTI offering and laboratory operations in Plano, Texas. The Resolve test was uniquely designed for our urology cus
- PRMdxhealth to Release First Quarter 2026 Financial Results on May 13Mdxhealth to Release First Quarter 2026 Financial Results on May 13 Company to Host Conference Call with Live Q&A, May 13, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2026, after market close on Wednesday, May 13, 2026. Title:Mdxhealth Presents First Quarter 2026 Financial Results andCorporate Update Conference Call and WebcastDate:May 13, 2026Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-800-245-3047Belgium: 0800 72 519United Kingdom: 0808 101 1183Conference ID:
- SECSEC Form 6-K filed by MDxHealth SA6-K - MDxHealth SA (0001872529) (Filer)
- INSIDERSEC Form 3 filed by new insider Mcgarrity Michael3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sollee Joseph3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bednarski Eric3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bellano John3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kalfus Ron3 - MDxHealth SA (0001872529) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hardison Don M3 - MDxHealth SA (0001872529) (Issuer)
MDXH FAQ
7 questionsWhat does MDxHealth SA do?
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth...Where does MDXH stock trade?
MDxHealth SA (MDXH) is listed on NASDAQ.What sector and industry is MDXH in?
MDxHealth SA operates in the Health Care sector, Medical Specialities industry.When did MDxHealth SA go public?
MDxHealth SA (MDXH) completed its IPO in 2021.What are analysts saying about MDXH?
MDxHealth SA has had 5 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2026-05-14. Recent price targets range from $700.00 to $1800.00.What companies are similar to MDXH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare MDXH side-by-side with any of them on Quantisnow.How can I track MDXH on Quantisnow?
Quantisnow aggregates MDxHealth SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDXH to receive live email and push alerts on every new disclosure.